Halotestin vs PT-141
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both Halotestin and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Halotestin PT-141
Weight 336.44 Da —
Half-life ~9.5 hours ~2.7 hours
Type 9-fluoro-11-beta-hydroxy-17-alpha-methyltestosterone (C20H29FO3) Melanocortin receptor agonist
Key Benefits
Halotestin
01 Dramatic increase in strength and power output without water retention
02 Pronounced increase in aggression and competitive drive
03 Does not aromatize to estrogen, producing a hard and dry appearance
04 Enhances red blood cell production and oxygen-carrying capacity
05 Rapid onset of effects, typically noticeable within days
06 Uniquely suited for pre-competition or pre-meet peaking protocols
07 Short cycle duration limits cumulative exposure
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Halotestin
10-20 mg/day / Split into 2 doses daily (morning and pre-training)
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Halotestin
Severe hepatic stress (elevated ALT, AST, GGT, bilirubin)
Pronounced aggression and irritability
HDL cholesterol suppression and LDL elevation
Elevated blood pressure
Headaches (frequently reported, may be related to blood pressure changes)
Suppression of endogenous testosterone production
Oily skin and acne
Decreased appetite (potentially related to liver stress)
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Known or suspected prostate cancer
Breast cancer in males
Pregnancy (Category X - causes fetal harm)
Active liver disease or existing hepatic impairment
Severe cardiovascular disease or uncontrolled hypertension
Hypercalcemia
Nephrosis or nephrotic phase of nephritis
History of cholestatic jaundice or hepatic dysfunction from prior anabolic steroid use
Hypersensitivity to fluoxymesterone or any formulation component
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Halotestin PT-141
Status Well Studied FDA Approved
References 5 studies 4 studies
Latest October 2023 2022
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.